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Abstract
Background: Cyclophosphamide (CP) and ifosfamide (IP) contaminations have been detected in hospital environments. This study 
was conducted to determine if there was any contamination in the spaces (floors and door handles) between the hospital exit and 
the  antineoplastic drugs (ADs) preparation and administration units. At the  same time, the  authors proposed a  new automation 
of the analytical procedure to considerably decrease the time needed for sample preparation and analysis. Material and Methods: 
To evaluate the ADs contamination of surfaces, 829 wipe tests were performed in a campaign involving 3 hospitals located in Italy. 
Sampling was performed using an innovative kit. The levels of ADs were measured in each wipe sample using liquid chromatography/
triple quadrupole. Results: On-line solid-phase extraction guarantees the construction of a robust and reproducible analytical me-
thod. The CP and IP recoveries from stainless steel, polycarbonate and polyvinyl chloride ranged >80%, and the wipe holders and 
the automation tested ensured desorption efficiencies close to 100% for both the ADs. Of the 552 wipes taken on the spaces between 
the hospital exit and the preparation, administration and pharmacy warehouse units, 22 were greater than or equal to the limit of qu-
antification, all adjacent to the administration units. Conclusions: This study provides an insight into the exposure situation against 
ADs residues. In order to improve environmental monitoring programs, the authors propose to evaluate the ADs contamination also 
outside the preparation, administration and pharmacy warehouse units. Med Pr. 2020;71(5):519–29
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Occupational exposure of healthcare workers to an-
tineoplastic drugs (ADs) has been studied since 
the  1970s  [1]. Ifosfamide (IP) and cyclophosphamide 
(CP) are commonly used oxazaphosphorines. To cause 
cell death, the alkylating agents CP and IP, as prodrugs, 
required biotransformation into their metabolic prod-
ucts to interact with DNA; only CP is recognized as car-
cinogenic to humans by the  International Agency for 
Research on Cancer. Studies have revealed that adverse 
health outcomes, such as genetic damage [2], reproduc-
tive effect or miscarriages [3], can be associated with oc-
cupational exposure to ADs. In Italy, the consumption 
of CP and IP exceeds 500 kg/year and is second to that 
of 5-fluorouracil [4].
Since 2004, the European community has promot-
ed the implementation of administrative and engineer-
ing controls across member states, in order to provide 
healthcare workers with the highest protection, and to 
https://doi.org/10.13075/mp.5893.00931
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warrant the  use of appropriate and validated proce-
dures for handling hazardous drugs. In February 2019, 
the European Parliament approved amendments to Di-
rective 2004/37/CE on carcinogens and mutagens and 
their implications for the healthcare sector (the Carcin-
ogens and Mutagens Directive)  [5]. Recommendation 
No. 11 from “Preventing occupational exposure to cyto-
toxic and other hazardous drugs. European Policy Rec-
ommendations” puts an effort into the use of environ-
mental monitoring procedures to detect how the drugs 
in question are released and spread, and thus to control 
and improve the  effectiveness of protective measures 
and equipment [6].
Recently, the European Biosafety Network has pub-
lished a  brochure in 8 languages on the  amendments 
where a  value of 0.1 ng/cm2 of the  surface threshold 
contamination is recommended for ADs [7]. Until to-
day, several manuscripts  [8–10] have been published 
showing that ADs were detected in urine samples of 
healthcare workers employed in preparation and ad-
ministration units. The  dermal absorption is the  ma-
jor exposure route  [11]; direct contact with the  drugs 
(manipulate vials producers and/or pharmacologi-
cal solutions in intravenous bags), or indirect contact 
as a result of touching contaminated surfaces, could be 
considered the main routes of dermal exposure. By per-
forming wipe sampling on the exposed surfaces, the po-
tential risk for dermal contact can be monitored. In ad-
dition, in January 2019, the  American Conference of 
Governmental Industrial Hygienists (ACGIH) firstly 
introduced a  new category of the  limit value referred 
to surface contamination, called the threshold limit val-
ue – the surface level. Surface limits for ADs are still not 
proposed by ACGIH but the need to quantitate harmful 
substances in order to control and reduce the contact 
from surfaces is now considered and ruled about.
Conflicting results concerning the  relationship be-
tween surface ADs contamination and professional ex-
posure are reported in literature [12]. Consequently, no 
exposure limits for ADs are proposed by any govern-
mental industrial hygiene association since there are no 
clear exposure levels known. Instead, the “as low as rea-
sonably achievable” principle is applied, but the  max-
imum exposure reduction cannot be demonstrated 
without the quantitative proofs of environmental con-
tamination. To guarantee the accuracy of ADs exposure 
evaluation, both in occupational and domestic scenar-
ios, Kromhout [13] recommended a quantitative expo-
sure assessment. Consequently, independent guidelines 
based on the percentile values for several ADs were sug-
gested by several authors [14–16] with the aim of mon-
itoring compliance with procedures, cleaning effective-
ness, and pollution’s persistency over time. Actually, ADs 
contamination in hospital environments and on equip-
ment is the  consequence of their massive use  [17,18]. 
Moreover, patients can carry ADs contamination in do-
mestic scenarios [19], and it eventually involves not on-
ly surfaces in the house environment but also the soil 
and superficial water  [20]. Hamscher et  al.  [21] have 
shown that there might be a  potential contamination 
risk when administering ADs in veterinary medicine. 
In  a  healthcare environment, ADs contamination can 
be present both in preparation units, due to pure drugs 
handling, and in administration units.
To evaluate the ADs carry-over, the authors of this 
study performed an analysis of wipe test results focusing 
on the spaces between the hospital exit and the prepa-
ration, administration and pharmacy warehouse units. 
At the same time, they proposed a new automation of 
the analytical process that leads to a reduction of time 
for sample preparation and analysis.
MATERIAL AND METHODS
Experimental design
In this study, the authors conducted the ADs environ-
mental assessment based on 829 wipe samplings per-
formed in 3 hospitals located in Italy in 2018. Gen-
erally, ADs contamination was estimated by wiping 
400 cm2 surfaces of the floor, handles or other plain ar-
eas where healthcare workers and oncologic patients 
involved in therapies could eventually determine an 
unwanted drug spread. Thus, these findings proved 
helpful in identifying the potential sources or routes of 
accidental exposure.
In particular, the sampling included:
 ■ floors and handles of exit doors between the prepa-
ration, administration and pharmacy warehouse 
units, and the hospital hall (552 wipes);
 ■ the administration units, and in particular floors 
and handles of exit doors, nurses’ gloves, drip 
rods, and the  outer surface of ADs infusion sacks 
(277 wipes). Wipes were sampled at the beginning 
(B) and at the  end (E) of the  work shift (WS) for 
3 consecutive days in a week.
Moreover, wipe tests were taken from the  surface 
of 25 drug vials and on related primary packaging of 
CP (Endoxan powder form, 1 g, batch 8D158B, Baxter) 
and IP (Holoxan powder form, 1 g, batch 8E076A, Bax-
ter). The surfaces of the vials had been removed from 
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the primary packaging just before the wipe tests were 
performed.
The volume of ADs administration units ranged 
13 076–19 096 therapies per hospital in a year. Italian 
hospitals follow the national guidelines [22]:
 ■ the staff were skilled in safety equipment and main-
tenance, research updates, and emergency care;
 ■ to avoid any leak of hazardous substances (Chemo-
Clave, ICU Medical Inc.; CareFusion, Becton Dick-
inson; Cyto-Set, B-Braun) closed-system devices 
were introduced;
 ■ specific cleansers were employed for floors (a solu-
tion of 0.2% Marseille soap, then a  cleaning step 
with 0.115% sodium hypochlorite, and finally 70% 
ethanol) and for smaller areas (Alcavis Bleach-Wipe 
1:50, Angelini Pharma Inc.). Four IIA-2 class bio-
safety cabinets were at the centralized ADs prepa-
ration units, which were protected by an anteroom. 
The levels of CP and IP were measured in each wipe 
sample by liquid chromatography (LC) and triple 
quadrupole (TQ) mass spectrometry (MS/MS) in-
struments.
Wipe sampling
In  this study, the  authors developed a  new wipe test 
kit, as previously described [14,23], which includes all 
the equipment required for sampling (Figure 1): non-
woven fabric wipes soaked with a water/methanol solu-
tion, put in a wipe cartridge kit (WCK) with a GH Poly-
pro filter, tweezers with disposable pipette tips, and 
a  handbook in which the  wipe sampling technique 
is described. On plain surfaces, a  20×20 cm area was 
wiped in 3 directions, while smaller areas were wiped 
recording the exact sampled surface. The wipe was elut-
ed using 2 ml of a water/methanol solution with inter-
nal standards, and it was put into the WCK using Au-
tomated Wipe Desorption (Chromline) mounted on 
a Flex GC autosampler (EST Analytical) equipped with 
WCK trays and a 2.5 ml headspace syringe.
Analytical procedures
First, CP and IP purification was performed with an 
Oasis Hydrophilic Lipophilic Balance (HLB) 25 μm, 
2.1 mm internal diameter, 20 mm length column (Wa-
ters, ref. 186002036) used as on-line solid-phase ex-
traction (SPE) and coupled to the  Alliance e2695 Se-
lector Valve (Waters) (Figure 2), installed on LC-Quat-
tro Micro (Waters) TQ-MS/MS. The  ADs separation 
procedure was performed with an Atlantis T3, 3 µm 
2.1×100  mm column (Cat. No. 186003718, Waters) 
at 25°C. The gradient (a 0.1% formic acid solution [A] 
and a  0.1% formic acid in 60:40 acetonitrile:metha-
nol solution [B]) used for chromatographic separation 
is shown in Table 1. The flow rate was 0.3 ml/min and 
100.0 µl of the  injection volume was set for desorbed 
wipes. The  MS utilized multiple reaction monitoring 
(MRM) and positive electrospray ionisation (ESI+) 
for CP precursor m/z 261.19 > product m/z 106.01, 
IP 261.20 > 92.00, daunorubicin (internal standard, IS) 
528.26 > 321.12, trophosphamide (IS) 323.21 > 154.02, 
cephalomannine (IS) 832.49 > 264.19.
Validation study
The calibration curve was carried out by analyzing 
wipes doped with mixed standard solutions of IP and 
CP at 6 concentration levels (1.25, 2.5, 5.0, 10.0, 20.0, 
and 40 ng/wipe), blank wipe samples and wipes spiked 
with the IS solution only. Five replicates of each level 
were performed, and the  curve was obtained by plot-
ting the  peak area ratio between each analyte and IS, 
vs. the nominal concentration of each calibration lev-
el. To obtain the best function between the calibration 
levels, a  linear regression approach was performed. 
1 – safe transport box, 2 – wipe cartridge kit (WCK), used for automatic desorption, 
preassembled with 5×5 cm 3-layer nonwoven fabric with 50-position WCK trays, 
3 – tablet with a barcode reader, 4 – CD instruction manual with photos and a video 
on the correct technique for obtaining wipe samples, 5 – tweezers with a joint for 
disposable pipette tips, 6 – tweezer tips, 7 – tweezer tip waste container, 8 – wipe 
sampling of a surface in laminar flow hood, 9 – wipe insertion in a bar-coded WCK 
after the surface sampling.
Figure 1. Wipe sampling kit used in a campaign involving 
3 hospitals located in Italy in 2018
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The slopes (m) and intercepts (b) of the calibration lines 
were calculated with the least-squares linear regression 
analysis, using the following equation:
 y = mx + b (1)
where:
y – ratio between the chromatographic area of the analyte and 
its IS,
x – analyte concentration.
The limit of detection (LOD) was estimated as:
 LOD = (3SEb + b) / m (2)
where:
SEb - intercept standard error.
The limit of quantification (LOQ) was obtained us-
ing 10 SEb, which corresponds to 3.3 LOD. Method re-
peatability was verified in terms of precision from with-
in- and inter-session standard analysis. Ten replicates 
of low- (2 ng/ml) and high-level (20 ng/ml) standards 
were performed, and the relative coefficient of variation 
(CV) on the  same day was reported as within-session 
repeatability. Inter-session repeatability was thus esti-
mated by CV from daily results of 3 low- and high-level 
standards replicates for 10 days.
Accuracy was determined on the same day by mean 
recoveries of 10 low- and high-level standard replicates, 
reported as the  percentage ratio between the  revealed 
and nominal concentrations. To validate method accu-
racy, it was tested using the U.S. Food and Drug Admin-
istration requirements. Low- and high-level standards 
were analyzed in every session from a new CP and IP 
solution with internal standards to assure the validation 
of results in the analytical session.
Then, ADs wipe sampling recoveries were estimated 
as the percentage of decontamination from doped sur-
faces. The authors also analyzed samples (0.05 ng/cm2 
and 0.4 ng/cm2) from stainless steel, smooth and less 
smooth 20×20 cm plates, doped with 20 ng and 100 ng 
of ADs, respectively, and diluted 1:5 with a water/meth-
anol solution (50:50) before the injection, in order to be 
compliant with the calibration curve. The stableness of 
the spiked wipe was evaluated at 4°C between 4–24 h. 
Wipe desorption efficiency was estimated as the differ-
ence of response between the doped wipes and the test-
ed nominal ADs solution. The  matrix effect was also 
evaluated for each AD, as a mean relative ionisation re-
covery for the analytes, calculating the response decline 
percentage between the analytes spiked into the eluate, 
after blank wipe extraction, and the analyte directly in-
jected into the mobile phase. The Stata data analysis and 
statistical software (StataCorp LLC) were utilized to 
























































Position A of the valve is set for on-line solid phase extraction (SPE) sample loading and to discharge hydrophilic and ionic compounds washing in the waste. After 4 min 
of runtime, position B is set for SPE sample elution and chromatographic separation by the analytical column.
Figure 2. The mobile phase from liquid chromatography (LC) flows into the Selector Valve (Waters) after the sample injection – the system 
employed in the analysis of wipe sampling performed in a campaign involving 3 hospitals located in Italy in 2018
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RESULTS
Wiping and desorption
The wiping procedure utilized in this study, based on 
the  use of tweezers instead of gloves, as was done by 
other authors, allows to a reduce the sampling time, cost 
(as replaceable tips used with the tweezers are cheaper 
than gloves), and the contamination risk. The CP and IP 
recoveries from stainless steel, polycarbonate and poly-
vinyl chloride were >80%. Inserting the  wipes into 
the  holder and automating the  procedure assured de-
sorption efficiencies close to 100%.
Analyses
The on-line SPE by OASIS HLB was used instead of 
the  conventional C18-cartridge SPE due to its better 
chemical stability in extreme pH conditions. Further-
more, the polymeric column sustained lower back pres-
sure than the silica sorbent, and this characteristic must 
be considered in the  method development in order to 
safeguard the  column performance. For all the  test 
compounds, the  analytical curves proved linear in the 
whole concentration range, with correlation coefficients 
(r2) >0.99. The  intra- and inter-day variability for all 
compounds ranged 3.5–7.5%, and the average intra-day 
accuracies were sufficient. The LOQs equaled 0.270 and 
0.217 ng/wipe for CP and IP, respectively (Table 2).
Data distribution
Of the 552 wipes taken on the floors and door handles 
of the spaces between the hospital exit and the prepa-
ration, administration and pharmacy warehouse units, 
22 were ≥LOQ (4%), all adjacent to the  ADs admin-
istration units; of these, 4 were taken at B-WS and 18 
at E-WS. Positive determinations (6% for a  total of 
277 wipe tests) for at least 1 AD at B-WS (No. 3) and at 
E-WS (No. 14) were determined on samples taken from 
the  administration units: in detail, drip rods (No. 2), 
nurse call buttons (No. 1) and the floor, tap, and toilet 
seat of the bathrooms (No. 14). Also, as regards the ad-
ministration units, no positive CP and IP determina-
tions were detected on the gloves of the nurses, the floor 
under the drip rods, and the outer surface of the ADs 
sacks before and after the infusion (Table 3).
Surface contamination of CP and IP packaging
Certain amounts of IP (ranging 6.7–44.2 pg/cm2) were 
found on the surfaces of all the vials investigated that 
had been removed from the outer package. No CP and 
IP were found on the investigated primary packaging.
DISCUSSION
Nowadays, the  sensitivity and specificity of analytical 
methods are not enough to detect ADs [12,24]. The au-
thors of this study proposed the  wipe test, a  method 
largely used by industrial hygienists and the  unique 
method that can detect ADs at low concentrations, as 
pg/cm2. Preceding studies showed that solvents and 
clean-up steps were often used to extract and elimi-
nate interfering substances from the wipe test [12]. This 
process requires many manual operations and it caus-
es uncertainty of the  determination, higher costs and 
a possible analyte loss. Therefore, the authors developed 
a method that combined the on-line SPE qualities with 
the LC-MS/MS quantitation.
The interest in simultaneous determinations of ADs, 
using chromatographic separation, has grown in recent 
years within the scientific community [25,26]. The au-
thors proposed the  use of the  Atlantis T3 LC analyti-
cal column. It is a silica-based, reversed-phase C18 col-
umn that provides equalized retention of low-polar 
and non-polar compounds: trifunctional C18 alkyl 
phase promotes polar compound retention and aque-
Table 1. Selector Valve (Waters) position for on-line solid phase extraction (SPE) loading and elution gradient for liquid chromatographic 




[%] Selector Valve position
A B
0.0–4.0 95 5 A
4.1–7.0 60 40 B
7.1–11.0 40 60 B
11.1–17.0 15 85 B
17.1–21.0 100 0 B
A – 0.1% formic acid solution, B – 0.1% formic acid in 60:40 acetonitrile:methanol solution.
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ous mobile phase compatibility. Its on-line coupling 
with the Oasis HLB clean-up cartridge offers an analyt-
ical innovation: thanks to the use of the Selector Valve 
developed by Waters, it is possible to load, elute and in-
ject the sample into the LC with the sole aid of the chro-
matographic system pumps, without the  need to in-
stall external pumps. This approach guarantees the con-
struction of a robust and highly reproducible method. 
In particular, the Oasis HLB allows to elute, by modify-
ing the pH of the mobile phase, a substance with differ-
ent pKa. Compared to other methods, the on-line SPE 
allows a lower consumption of solvents, a reduction in 
the cost of disposal of conventional SPE cartridges, and 
a reduced use of operator time.
The XYZ robotic system reduces manual operations 
and enables automated wipe desorption. Using bar-cod-
ed WCK, each wipe was traced by a  unique tracking 
number. Moreover, using a data management system (Bi-
ka LIMS), all the  information concerning the sampling 
process, analysis and quantitation can be integrated.
The main aspects concerning the risk to healthcare 
workers are about the ADs toxicity and how these drugs 
can enter the body. In  fact, ADs environmental mon-
itoring has been suggested by different guidelines re-
leased by international organizations, as the  Occupa-
tional Safety and Health Administration and the Euro-
pean Policy Recommendation [6].
Generally, drugs with a  low molecular weight 
(<500 Da) [11] are the most inclined to dermal absorp-
tion. While reviewing literature, it was found that a der-
mal occupational exposure limit was proposed for CP, 
equal to 4000 pg/cm2  [19]. Data from animal studies 
show that the  risk of developing cancer was 100–600 
per million [27]. For the quantitative evidence of envi-
ronmental CP and IP contaminations, a traffic-light col-
or-coding reference values model was proposed by Ses-
sink [16], while Kiffmeyer et al. [15] developed an in-
dependent guideline based on the 90th percentile val-
ues of 8 ADs. Hedmer et al. [28] and Sottani et al. [29] 
suggested hygienic guidance values (HGVs) for dif-
ferent kinds of surfaces at hospital. Finally, Dugheri 
et al. [14,23] recommended both HGVs and surface ex-
posure levels (SELs), respectively, based on the percen-
tile of wipe sampling data distributions (Table 4).
Table 2. Calibration curve parameters and the limit of detection (LOD) and the limit of quantification (LOQ) for cyclophosphamide (CP) 
and ifosfamide (IP) in wipe samples carried out in a campaign involving 3 hospitals located in Italy in 2018
Variable Cyclophosphamide Ifosfamide
Molecular weight [g/mol] 261.08 261.09
Ion [m/z]
precursor ion 261.19 261.20
quantitative product 106.01 92.26
qualitative product 140.21 182.12
Least-squares linear regression parameters
m 84.39 65.15
b 0.31 0.17
Coefficient of correlation 0.99 0.99
Limit of detection (LOD)
ng/wipe 0.082 0.066
pg/cm2 0.2 0.1
Limit of quantification (LOQ)
ng/wipe 0.270 0.217
pg/cm2 0.6 0.5
Within-session accuracy (10 replicates, 2 levels*) 7.7 3.8
Within-session repeatability (10 replicates) 3.5 5.8
Inter-session repeatability (3 replicates, 2 levels*) 7.5 4.8
Within-session accuracy, precision of the assay in terms of within- and inter-session repeatability are reported as the coefficient of variation (CV) and the number of low-  
 and high-level standards replicates
* 2 ng/ml and 20 ng/ml.
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The authors of this study considered the floors and 
door handles of the locations outside the ADs prepara-
tion, administration and pharmacy warehouse units in 
order to analyze the contamination containment, and 
to identify the possible routes of the substance migra-
tion through the preparation, distribution and admin-
istration scenarios. These ubiquitous environmental 
contaminations could lead to the  exposure of work-
ers who are not directly involved in ADs administra-
tion or preparation. This kind of interaction represents 
a potential hazard for these employees that generally 
use less protective clothing [30]. In  these campaigns, 
the results showed that positive wipe tests for CP and 
IP were revealed on the  spaces between the  hospital 
exit and the administration units; a percentage simi-
lar to that found 10 years ago [14,23], or currently by 
other authors [31], in the preparation and administra-
tion units. No contamination from CP and IP was de-
tected in the  adjacent spaces to the  preparation and 
pharmacy warehouse units, demonstrating that the in-
ternal procedures were complied with. In the admin-
istration units, the patient represents a variable that is 
still difficult to control and nurses may have difficulty 
managing [32].
CONCLUSIONS
This study gives an overview of exposure to ADs resi-
dues in the spaces adjacent to the administration rooms. 
In the authors’ opinion, there is a need to:
 ■ adopt certain procedures to help patients contain 
the contamination of ADs,
 ■ extend the protocol of cleaning of the administra-
tion units also to adjacent spaces of the hospital out-
bound path,
 ■ introduce new sampling points by wipe tests also in 
the  adjacent areas of the  preparation, administra-
tion and pharmacy warehouse units.
Furthermore, another potential source of exposure 
to ADs was investigated: unbroken CP and IP drug vi-
als, and their outer packaging were tested. This con-
tribution showed that only small IP quantities were 
found on vial surfaces removed from the outer package. 
Thanks to this study, it was found that the clean-up pro-
cesses and manufacturing are key steps of ADs handling 
for preventing contamination at hazardous levels.
Based on this experience, the  authors recommend 
that patients must be made conscious of the potential 
risk for other people, considering that the contamina-
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faces. Moreover, for this reason, hygienic and protec-
tive protocols should also be introduced for the domes-
tic environment to reduce the risk of exposure.
Professor Andrea Farioli (1981–2020), M.D., Ph.D., a bril-
liant colleague and a sincere friend, suddenly passed while he 
was performing significant epidemiological research on the 
SARS-CoV-2.
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